Progyny (NASDAQ:PGNY) Stock Gets Price Target Boost from Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised Progyny’s price target to $35 from $31 and maintained an overweight rating, implying about 16.3% upside from the prior close. Analysts overall have a “Moderate Buy” consensus and an average target of $34.50.
• Progyny reported quarterly EPS of $0.52, above the cited $0.31 consensus, while revenue rose 8.9% year over year to $341.25 million, slightly exceeding estimates.

Progyny (NASDAQ:PGNY - Get Free Report) had its price target increased by Cantor Fitzgerald from $31.00 to $35.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Cantor Fitzgerald's price target would indicate a potential upside of 16.28% from the company's previous close.

A number of other equities research analysts have also issued reports on PGNY. KeyCorp lifted their target price on Progyny from $30.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Citizens Jmp lifted their price objective on shares of Progyny from $31.00 to $33.00 and gave the company a "market outperform" rating in a report on Tuesday, September 8th. BTIG Research increased their price objective on shares of Progyny from $30.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, July 24th. Truist Financial raised their price objective on Progyny from $33.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Finally, Zacks Research downgraded Progyny from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 19th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Progyny Trading Up 3.6%

PGNY opened at $30.10 on Thursday. The stock has a market capitalization of $2.31 billion, a P/E ratio of 32.72, a P/E/G ratio of 2.01 and a beta of 0.97. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The firm's fifty day simple moving average is $27.11 and its 200 day simple moving average is $24.49.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.21. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm had revenue of $341.25 million during the quarter, compared to analysts' expectations of $340.76 million. During the same quarter in the prior year, the company earned $0.15 EPS. The company's revenue was up 8.9% on a year-over-year basis. On average, equities research analysts predict that Progyny will post 1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the transaction, the executive vice president directly owned 75,816 shares in the company, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa B. Cummings sold 1,879 shares of the business's stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at $1,861,888. The trade was a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,282 shares of company stock valued at $475,790 over the last 90 days. 9.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Progyny

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Progyny during the second quarter worth about $334,426,000. Bank of America Corp DE bought a new stake in Progyny in the 2nd quarter valued at about $17,264,000. William Blair Investment Management LLC acquired a new position in shares of Progyny during the 2nd quarter worth approximately $16,807,000. Danske Bank A S acquired a new position in shares of Progyny during the 2nd quarter worth approximately $15,243,000. Finally, Jupiter Topco LLC bought a new position in shares of Progyny during the second quarter worth approximately $12,986,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter EPS of $0.52, up from $0.15 a year earlier, and revenue of $341.25 million, an 8.9% year-over-year increase. Revenue narrowly topped one estimate of $340.76 million; the company characterized the quarter as a record. Progyny Announces Third Quarter 2026 Results
• Neutral Sentiment: Analyst benchmarks differed: one source cited a $0.31 EPS consensus, while Zacks cited $0.51. Thus, the earnings beat appears substantial against the lower estimate but modest against the higher one, while revenue was close to expectations. Progyny Tops Q3 Earnings and Revenue Estimates

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.